Financial Analysis: Tango Therapeutics (NASDAQ:TNGX) and Inovio Pharmaceuticals (NASDAQ:INO)

Tango Therapeutics (NASDAQ:TNGX) and Inovio Pharmaceuticals (NASDAQ:INO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Tango Therapeutics and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Volatility & Risk

Tango Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Tango Therapeutics and Inovio Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	2	2	13	0	2.65
Inovio Pharmaceuticals	1	2	5	0	2.50

Tango Therapeutics presently has a consensus target price of $44.62, suggesting a potential upside of 96.37%. Inovio Pharmaceuticals has a consensus target price of $3.17, suggesting a potential upside of 425.68%. Given Inovio Pharmaceuticals’ higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Tango Therapeutics.

Insider and Institutional Ownership

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Tango Therapeutics and Inovio Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38 million	61.41	-$101.59 million	($0.85)	-26.73
Inovio Pharmaceuticals	$60,000.00	1,038.14	-$84.95 million	($0.91)	-0.66

Inovio Pharmaceuticals has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Tango Therapeutics beats Inovio Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.